Latest Insights & Developments

Commercialization in Pharma, MedTech, and Biotech requires more than advances in R&D and compliance technology. While much of the life sciences IT landscape has focused on drug development and regulatory requirements, critical commercial functions such as go-to-market strategy, market access, and execution have remained underserved. At the same time, legacy systems, fragmented data, and increasing regulatory complexity continue to slow growth. Vamstar's Polaris AI addresses these challenges by combining market intelligence, pricing optimization, and regulatory compliance tracking into a single AI-powered platform, enabling faster, more informed decisions across more than 100 markets. Discover how AI is transforming commercial execution in the life sciences industry.

Discover how Vamstar leverages AI-powered data curation and prescriptive contracting to streamline procurement, strengthen compliance, and optimize bid strategies—enabling MedTech and pharma organizations to accelerate decision-making, reduce risk, and gain a competitive advantage.

Discover how AI-powered healthcare contract management improves accuracy, streamlines workflows, and increases bid success rates in the competitive MedTech industry.

The EU wants quality to count in public procurement, but a 30% weighting and broad derogations could leave price-only contracting intact. Learn why medtech suppliers need an award-level baseline before the new rules take effect.

MedTech has expanded EBITDA margin by just 10 basis points since 2017, while technology gained 460. This article examines where revenue leaks across bids, pricing and contracts, and why boards should direct AI towards revenue growth, not just headcount reduction.

Tariff volatility is exposing gaps in MedTech contracts, leaving suppliers vulnerable to rising costs and margin erosion. This article explores how Clause Engineering can strengthen tariff adjustment rights, address supply and country-of-origin risks, and establish clear tariff refund mechanisms. Discover four critical contract clauses and the priorities commercial leaders should address before the 2027 contracting cycle to protect margins and improve pricing flexibility.

Section 232 tariffs are intended to bring medical device manufacturing back to the US. But MedTech’s regulatory complexity, global supply chains and long validation cycles make reshoring far harder than tariff policy assumes. As manufacturers absorb rising costs and selectively diversify sourcing, the bigger question is whether tariffs can actually deliver the domestic manufacturing shift policymakers are targeting.

The EU’s MDR transition gives eligible MedTech manufacturers until 2027 and 2028 to complete the move to the new regulatory framework. But the additional runway is already influencing portfolio decisions, certification priorities and future contract opportunities. With the European Commission also proposing targeted MDR and IVDR reforms, manufacturers need to understand what the transition means for products, market access and commercial strategy. Read on to explore how MedTech leaders can turn regulatory runway into commercial advantage.